New Zealand markets closed

BioMarin Pharmaceutical Inc. (BM8.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
62.30+0.20 (+0.32%)
At close: 09:18AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
2,588,398
2,419,226
2,096,039
1,846,275
1,860,455
Cost of revenue
504,402
514,854
483,669
470,515
524,272
Gross profit
2,083,996
1,904,372
1,612,370
1,375,760
1,336,183
Operating expenses
Research development
786,338
746,773
649,606
628,793
628,116
Selling general and administrative
1,009,112
937,300
854,000
759,400
737,700
Total operating expenses
1,854,953
1,746,273
1,566,406
1,450,093
1,428,016
Operating income or loss
229,043
158,099
45,964
-74,333
-91,833
Interest expense
16,404
16,741
15,377
14,744
27,480
Total other income/expenses net
13,702
-10,538
101,550
3,846
55,462
Income before tax
298,679
188,563
149,576
-75,350
-48,997
Income tax expense
42,090
20,918
8,015
-11,270
-903,026
Income from continuing operations
256,589
167,645
141,561
-64,080
854,029
Net income
256,589
167,645
141,561
-64,080
854,029
Net income available to common shareholders
256,589
167,645
141,561
-64,080
854,029
Basic EPS
0.77
0.89
0.76
-0.35
4.75
Diluted EPS
0.77
0.87
0.75
-0.35
4.53
Basic average shares
187,222
187,834
185,266
182,852
180,804
Diluted average shares
191,056
191,595
188,963
182,852
191,678